Sold as Selenious Acid. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 15, 2026, FDA lists 11 applications for Selenious Acid (sold as Selenious Acid), first approved Apr 30, 2019, with 0 new uses approved and 0 published complete response letters.
| Apr 30, 2019 | Selenious AcidNDA 209379 · New active ingredient | Am Regent | 3 | Marketed |
| Feb 10, 2025 | Selenious AcidANDA 218779 | Fresenius Kabi USA | 0 | Discontinued |
| Feb 20, 2025 | Selenious AcidANDA 219547 | Sun Pharm | 0 | Marketed |
| Jun 11, 2025 | Selenious AcidANDA 219633 | Aspiro | 0 | Marketed |
| Jul 8, 2025 | Selenious AcidANDA 219629 | Gland | 0 | Marketed |
| Jul 21, 2025 | Selenious AcidANDA 218661 | Cipla | 0 | Discontinued |
| Dec 31, 2025 | Selenious AcidANDA 218536 | Stira | 0 | Marketed |
| Feb 3, 2026 | Selenious AcidANDA 219472 | Emerge Bioscience | 0 | Marketed |
| Jun 30, 2026 | Selenious AcidANDA 219322 | Zydus Pharms | 0 | Marketed |
| — | Selenious AcidANDA 219492 | Steriscience Pte. Limited | 0 | Discontinued |
| — | Selenious AcidANDA 220051 | Bpi Labs LLC | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius Kabi USA
Cipla
Zydus Pharms